Novel aryl(4-phenylpiperazin-1-yl)methanethione derivatives as new anti-Alzheimer agents: Design, synthesis, in vitro and in silico assays

dc.contributor.authorAnsari, Samira
dc.contributor.authorNoori, Milad
dc.contributor.authorPedrood, Keyvan
dc.contributor.authorMohammadi-Khanaposhtani, Maryam
dc.contributor.authorMoazzam, Ali
dc.contributor.authorHosseini, Samanesadat
dc.contributor.authorLarijani, Bagher
dc.date.accessioned2025-10-18T10:10:38Z
dc.date.created2022
dc.date.issued2022
dc.departmentFakülteler, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümü
dc.description.abstractIn this work, a new series of aryl(4-phenylpiperazin-1-yl)methanethione derivatives 4a-n was designed, synthesized, and evaluated against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and alpha glucosidase. Most of the synthesized derivatives were more potent than standard inhibitor donepezil against AChE and all the synthesized compounds were more potent than donepezil against BChE. Moreover, some of these new compounds were more potent than acarbose (positive control) against alpha glucosidase. The obtained results revealed that (3-chlorophenyl)(4-phenylpiperazin-1-yl)methanethione 4k and was the most potent compound against cholinesterase enzymes (AChE and BChE). Docking study of compound 4k in the active site of cholinesterase enzymes showed that this compound established important interactions with the main residues of the target enzymes. Druglikeness/ADME/Toxicity profile prediction of the most potent compounds also demonstrated that these compounds can be drug candidates and have the appropriate properties in terms of ADME and Toxicity. (c) 2022 Elsevier B.V. All rights reserved.
dc.identifier.doi10.1016/j.molstruc.2022.132945
dc.identifier.issn0022-2860
dc.identifier.issn1872-8014
dc.identifier.orcidSadeghian, nastaran/0009-0004-2966-9231
dc.identifier.orcidAnsari, Samira/0000-0002-1254-692X
dc.identifier.orcidTaslimi, Parham/0000-0002-3171-0633
dc.identifier.orcidLarijani, Bagher/0000-0001-5386-7597;
dc.identifier.scopus2-s2.0-85127622665
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1016/j.molstruc.2022.132945
dc.identifier.urihttps://hdl.handle.net/11772/21978
dc.identifier.volume1262
dc.identifier.wosWOS:000803814700009
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofJournal of Molecular Structure
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzWoS_20251016
dc.subject4-Phenylpiperazin
dc.subjectAcetylcholinesterase
dc.subjectButyrylcholinesterase
dc.subjectAlzheimer?S Disorder
dc.titleNovel aryl(4-phenylpiperazin-1-yl)methanethione derivatives as new anti-Alzheimer agents: Design, synthesis, in vitro and in silico assays
dc.typeArticle
dspace.entity.typePublication

Dosyalar